Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AVXL 
Anavex Life Sciences Corp (AVXL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: AVXL (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $34.33
1 Year Target Price $34.33
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.63% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 804.83M USD | Price to earnings Ratio - | 1Y Target Price 34.33 |
Price to earnings Ratio - | 1Y Target Price 34.33 | ||
Volume (30-day avg) 3 | Beta 0.83 | 52 Weeks Range 5.03 - 14.44 | Updated Date 09/15/2025 |
52 Weeks Range 5.03 - 14.44 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.41% | Return on Equity (TTM) -43.64% |
Valuation
Trailing PE - | Forward PE 3.95 | Enterprise Value 703661224 | Price to Sales(TTM) - |
Enterprise Value 703661224 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.54 | Shares Outstanding 85893800 | Shares Floating 83005224 |
Shares Outstanding 85893800 | Shares Floating 83005224 | ||
Percent Insiders 3.31 | Percent Institutions 38.4 |
Upturn AI SWOT
Anavex Life Sciences Corp
Company Overview
History and Background
Anavex Life Sciences Corp. was founded in 2004. It is a biopharmaceutical company focused on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimeru2019s disease, Rett syndrome, and Parkinsonu2019s disease.
Core Business Areas
- Drug Development: Development of novel therapeutics targeting sigma-1 receptor activation for various neurological disorders.
Leadership and Structure
Christopher U Missling, PhD, is the President and Chief Executive Officer. The company has a board of directors and a management team overseeing research and development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- ANAVEXu00ae2-73 (blarcamesine): An oral small molecule drug candidate currently in clinical development for the treatment of Alzheimer's disease, Rett syndrome, and Parkinson's disease dementia. While specific market share data is unavailable due to its development stage, success would position it against symptomatic and disease-modifying treatments. Competitors include Biogen (ADU), Eisai (LEQEMBI), and Eli Lilly (donanemab, in development).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurodegenerative diseases is characterized by high unmet needs, significant research and development investments, and regulatory complexities. It's a large and growing market driven by an aging population and increasing disease prevalence.
Positioning
Anavex is positioned as a company developing innovative treatments for neurological disorders by modulating the sigma-1 receptor. Its competitive advantage lies in its novel approach and potential disease-modifying effects.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease treatments is projected to exceed tens of billions of dollars annually. Anavex's positioning relative to this TAM depends on the clinical success and regulatory approval of its lead candidate, ANAVEXu00ae2-73. If approved, it can potentially capture a substantial share of the market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting sigma-1 receptor
- Potential disease-modifying effects
- Multiple clinical trials underway across different indications
- Experienced management team
Weaknesses
- High risk associated with drug development
- Limited commercialized products
- Dependence on clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Growing market for neurodegenerative disease treatments
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ESAIY
Competitive Landscape
Anavex faces intense competition from large pharmaceutical companies with greater resources and established market presence. Its competitive advantage lies in its novel therapeutic approach, but it faces challenges in funding, clinical development, and regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by preclinical and clinical development progress of its drug candidates, reflected in fluctuations in stock price based on news and trial results.
Future Projections: Future growth is contingent on the successful completion of clinical trials and regulatory approvals, especially for ANAVEXu00ae2-73.
Recent Initiatives: Recent initiatives include advancing ANAVEXu00ae2-73 in Phase 2 and Phase 3 clinical trials for Alzheimer's disease, Rett syndrome, and Parkinson's disease dementia.
Summary
Anavex Life Sciences is a high-risk, high-reward biopharmaceutical company focusing on novel treatments for neurodegenerative diseases. Its lead candidate, ANAVEXu00ae2-73, holds promise, but its success hinges on positive clinical trial outcomes and regulatory approval. The company needs to manage its cash flow carefully and navigate a competitive landscape dominated by larger players. Recent clinical trials show promise but more data needs to be obtained.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximations and may vary depending on the source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anavex Life Sciences Corp
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2006-08-02 | President, CEO, Secretary & Director Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 42 | Website https://www.anavex.com |
Full time employees 42 | Website https://www.anavex.com | ||
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.